Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 189 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: budesonide Clear all
Completed Phase 3 Interventional Results available

Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma

NCT00667992
View directory record Official record
Conditions
Asthma
Interventions
Budesonide HFA, Budesonide CFC
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

NCT06139991
View directory record Official record
Conditions
Heathy Participants
Interventions
Treatment A (BDA MDI HFO), Treatment B (BDA MDI HFA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

NCT01854047
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Not applicable Interventional Results available

Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide

NCT01219738
View directory record Official record
Conditions
Asthma
Interventions
Budesonide 360ug, Budesonide 720ug, Budesonide 1440ug, Budesonide720ug 4 times, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth

NCT01520688
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Fluticasone, Budesonide, Beclomethasone, Budesonide, Fluticasone
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Green Tree, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Phase 4 Interventional Results available

ED-Initiated School-based Asthma Medication Supervision

NCT03952286
View directory record Official record
Conditions
Asthma, Asthma in Children
Interventions
ED-Dispensing home and school supervision
Drug
Lead sponsor
University of Arizona
Other
Eligibility
6 Years to 12 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 19, 2026, 11:17 PM EDT
Not listed Phase 4 Interventional

Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease

NCT05364385
View directory record Official record
Conditions
Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity, Budesonide
Interventions
Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL), Infants in the control group (S/P group) receive placebo (Normal saline 1mL)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
Up to 18 Hours
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

NCT05477108
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 19, 2026, 11:17 PM EDT
Terminated Phase 2 Interventional Results available

Eosinophilic Esophagitis Clinical Therapy Comparison Trial

NCT01821898
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Oral Budesonide, Elimination diet
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

NCT04609878
View directory record Official record
Conditions
Asthma
Interventions
BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
2,274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
107
States / cities
Saraland, Alabama • Phoenix, Arizona • Sun City West, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 19, 2026, 11:17 PM EDT
Terminated Phase 2 Interventional Results available

The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis

NCT00805285
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis
Interventions
Combination Oral Budesonide and Rectal Hydrocortisone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)

NCT02736409
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Oral Budesonide Suspension (OBS), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 55 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 19, 2026, 11:17 PM EDT
Active, not recruiting Phase 3 Interventional Results available

The Budesonide in Babies (BiB) Trial

NCT04545866
View directory record Official record
Conditions
Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
Interventions
budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf)
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 48 Hours
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis

NCT00638456
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Budesonide plus Prevacid, placebo plus Prevacid
Drug
Lead sponsor
Ranjan Dohil
Other
Eligibility
1 Year and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 19, 2026, 11:17 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19

NCT04964414
View directory record Official record
Conditions
Dysosmia, Anosmia, Covid19
Interventions
Smell Retraining, Budesonide
Other · Drug
Lead sponsor
Amanda Stapleton
Other
Eligibility
6 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

Personalized Treatment Algorithms for Difficult-to-treat Asthma

NCT04179461
View directory record Official record
Conditions
Asthma in Children
Interventions
Cholecalciferol, antihistamine, Azithromycin, emollient cream, Fluticasone Propionate, Asthma Controller Medication
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis

NCT03705793
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Allergic Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis
Interventions
Mometasone Furoate Nasal Irrigation, Mometasone Nasal Spray
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Phase 1 Interventional

Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma

NCT01511302
View directory record Official record
Conditions
Asthma
Interventions
RNS60, Normal Saline, Budesonide
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Costa Mesa, California • Los Angeles, California • Riverside, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 19, 2026, 11:17 PM EDT
Completed No phase listed Observational

Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation

NCT07414134
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
3,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Gaithersburg, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose

NCT03250182
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT010
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 19, 2026, 11:17 PM EDT
Terminated Not applicable Interventional Results available

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

NCT00706446
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 19, 2026, 11:17 PM EDT
Active, not recruiting Phase 4 Interventional

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

NCT06422689
View directory record Official record
Conditions
Asthma
Interventions
Albuterol and budesonide inhalation aerosol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
North Hollywood, California • Walnut Creek, California • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 19, 2026, 11:17 PM EDT
Recruiting Phase 4 Interventional

Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis

NCT06076304
View directory record Official record
Conditions
Sinus Infection, Acute Sinusitis
Interventions
amoxicillin/clavulanate potassium, Placebo, Budesonide nasal spray
Drug
Lead sponsor
Daniel Merenstein
Other
Eligibility
18 Years to 75 Years
Enrollment
3,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Hyattsville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 19, 2026, 11:17 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478696
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
42
States / cities
Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 19, 2026, 11:17 PM EDT